van Geel RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, et al. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor
PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell
lung and pancreatic cancer. Br J Cancer 2020;122:1166-1174.
PMID: 32147669